PAP. Ian Andrews

P. Ian Andrews

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


P. Ian Andrews has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher Troedson

    T.Y. Nelson Department of Neurology and Neurosurgery, Children’s Hospital at Westmead, Westmead and University of Sydney, New South Wales, Australia (J.A., S.A.-H., R.C.D., D.G., S.G., M.P.M., C.T., R.I.W.).

    4 shared publications
  • Christina Miteff

    Department of Neurology, John Hunter Children’s Hospital, New Lambton Heights, New South Wales, Australia (C.M.).

    3 shared publications
  • Ferdinand Miteff

    Department of Neurology, John Hunter Hospital, Newcastle, Australia

    3 shared publications
  • Hugo Sampaio

    Department of Neurology, Sydney Children’s Hospital, Randwick, New South Wales, Australia (R.C.B., A.M.B., M.C., D.L.C., M.A.F., A.J., T.K., J.L., S.C.P., H.S., H.L.T., P.I.A.).

    3 shared publications
  • Kartik Dev Bhatia

    Department of Medical Imaging, Children’s Hospital at Westmead, New South Wales, Australia (K.D.B.).

    3 shared publications
  • Tejaswi Kandula

    Department of Neurology, Sydney Children’s Hospital, Randwick, New South Wales, Australia (R.C.B., A.M.B., M.C., D.L.C., M.A.F., A.J., T.K., J.L., S.C.P., H.S., H.L.T., P.I.A.).

    3 shared publications

Latest Publications

  • Eligibility for Thrombolysis for Pediatric Acute Ischemic Stroke

    by Romain C. Briest, Kartik D. Bhatia, Christina Miteff, Andrew Cheung, Jayne Antony, Simone Ardern-Holmes, Ann M. Bye, Michael Cardamone, Denise L. Chan, Russell C. Dale, et al.

    BACKGROUND: Thrombolysis is infrequently delivered to children with acute ischemic strokes (AIS). We explored potential eligibility for treatment with tPA (tissue-type plasminogen activator) for pediatric AIS. METHODS: This retrospective, multicenter, observational, cohort study reviewed children aged 29 days to 17 years with symptomatic AIS identified via Children’s Hospital Westmead, John Hunter Children’s Hospital, and Sydney Children’s Hospital between January 1, 2010, and December 31, 2019. Medical records were examined to evaluate eligibility for treatment with tPA based on established multinational and the 2026 American Heart Association guidelines, reasons for exclusion beyond delay to diagnosis, and long-term outcomes as pediatric modified Rankin Scale scores. We also explored additional exclusions and outcomes among children with small-vessel AIS and AIS in the context of brain tumors, who are currently excluded from tPA. RESULTS: A total of 135 patients with 139 symptomatic AIS were identified—median age, 6 years; 36% female patients; 73% presented via emergency departments; mean follow-up, 43 months; 12% deaths. Irrespective of delay to diagnosis, only 26 of 139 (19%) AIS were potentially eligible for treatment with tPA. Among patients potentially eligible for tPA, acute neuroimaging revealed large-vessel occlusions, unilateral focal cerebral arteriopathy, or extracranial dissections. Thirteen of 26 (50%) had nondisabled outcomes without tPA treatment. One hundred thirteen of 139 (81%) AIS were ineligible for treatment with tPA, irrespective of delay to diagnosis. All deaths occurred among patients excluded from tPA, predominantly related to underlying disorders. Fifty-four small-vessel AIS accounted for 39% of AIS. Eighteen (33%) had no additional ineligibilities to thrombolysis, among whom 10 had nondisabled outcomes without tPA. CONCLUSIONS: Based on current recommendations, 19% of symptomatic childhood AIS were potentially eligible for treatment with tPA, irrespective of delay to diagnosis. Selected patients with small-vessel AIS may offer an opportunity to extend the role of tPA. These observations may be relevant for optimizing pediatric stroke management strategies.

  • Thrombectomy Versus Medical Management for Pediatric Arterial Ischemic Stroke With Large Baseline Infarct

    by Kartik D. Bhatia, Prakash Muthusami, Carmen Parra-Farinas, Elizabeth Pulcine, Samyami Chowdhury, Nomazulu Dlamini, Ian Andrews, Sachin Gupta, Richard Webster, Christopher Troedson, et al.

    BACKGROUND: Multiple recent randomized trials have demonstrated the benefit of thrombectomy over medical management alone in adult patients with large vessel occlusion (LVO) stroke and large infarct on baseline imaging. Cohort studies have also identified improved functional outcomes in pediatric patients who received thrombectomy. However, the role of thrombectomy in pediatric stroke with large baseline infarct remains uncertain. METHODS: A case-control study was undertaken using pooled data from 3 cohort studies of pediatric stroke (Save ChildS [Safety and Outcome of Endovascular Recenalization in Childhood Stroke Study], Save ChildS Pro [Safety and Outcome of Endovascular Recenalization in Childhood Stroke Prospective Registry], Pediatric LVO Stroke Study). Pediatric patients of age 1 to 18 years with acute anterior circulation LVO stroke presenting within 24 hours since last seen well with an Alberta Stroke Program Early CT Score of 0 to 5 on CT or magnetic resonance imaging were included. Isolated M2 occlusion or focal cerebral arteriopathy–inflammatory subtype cases were excluded. Thrombectomy-treated patients were compared with patients who received medical management alone. The primary clinical outcome was the pediatric modified Rankin Scale score at 90 days, compared between groups using ordinal logistic regression. RESULTS: Of 56 pediatric patients with anterior circulation LVO and low Alberta Stroke Program Early CT Score presenting between January 1, 2000 and August 31, 2023 from 45 centers across Europe, North America, and Australia, 40 patients were eligible for inclusion (female: n=14, 35.0%; mean age, 9.1 years; range, 1.5–17; SD, 5.27). Thrombectomy-treated patients (n=24) had significantly better pediatric modified Rankin Scale scores at 90 days than medical management alone patients (n=16; odds ratio, 3.68 [95% CI, 1.11–12.21]; P =0.034). There was no significant difference between groups in the rate of symptomatic intracranial hemorrhage ( P =0.806). CONCLUSIONS: In this multicentre case-control study, pediatric patients (age, 1–18 years) with anterior circulation LVO stroke and low Alberta Stroke Program Early CT Score who received thrombectomy had significantly better functional outcomes than those treated with medical management alone. Exclusion of pediatric patients from thrombectomy based on low Alberta Stroke Program Early CT Score alone may not be appropriate.


  • Open Access

    WITHDRAWN: Eligibility for thrombolysis and outcome in pediatric acute ischemic stroke

    by Romain C. Briest, Kartik D Bhatia, Christina Miteff, Andrew Cheung, Jayne Antony, Simone Ardern-Holmes, Annie Bye, Michael Cardamone, Denise Chan, Russell Dale, et al.

    Background Thrombolysis is infrequently delivered to children with acute ischemic stroke (AIS). Consideration of eligibility criteria and outcomes after AIS may enhance utility of thrombolysis in pediatric AIS. Methods This retrospective observational study assessed eligibility for acute tissue plasminogen activator (tPA) and outcome in a 10-year population cohort of 151 children with AIS and a first symptomatic AIS cohort of 68 children. Outcomes among children with small vessel AIS, residual brain tumors and intracranial dissection, who are currently excluded from tPA, were explored to assess potential for benefit from tPA in these subgroups. Results Approximately 80% of each cohort were excluded from tPA, irrespective of delay to diagnosis, related to multiple underlying disorders. All deaths occurred among patients excluded from tPA. The minority eligible for tPA had large vessel occlusions, focal cerebral arteriopathy or extracranial dissections. More than half of eligible patients had non-disabled outcomes without tPA. Approximately 40% of both cohorts had small vessel AIS, more than half of whom were excluded from tPA for additional reasons. Among those not additionally excluded, 78-88% of each cohort had non-disabled outcomes without tPA. Among 12 patients excluded from tPA due to residual brain tumors, all had additional exclusions. In contrast, patients with AIS due to intracranial dissection infrequently had additional cause for exclusion and outcomes were relatively poor. Conclusions Only 20% of childhood AISs were eligible for tPA, irrespective of delay to diagnosis, and more than half of these patients manifest non-disabled outcomes without tPA, suggesting relatively restricted potential for benefit with tPA. Relaxation of some exclusions for selected patients may enhance beneficial delivery of tPA.

  • Open Access

    Urgent computed tomography angiography in paediatric stroke

    by Romain C. Briest, Andrew K. Cheung, Tejaswi Kandula, Michael Cardamone, Sekhar C. Pillai, Hugo Sampaio, Hooi‐Ling Teoh, Richard I. Webster, Jason D. Wenderoth, P. Ian Andrews

    Aim: To improve delivery of acute therapies for acute ischaemic stroke (AIS).Method: We identified factors influencing the speed of diagnosis and delivery of acute therapies in a prospective cohort of 21 children with suspected AIS (eight with AIS, 13 stroke mimics) and explored them in a retrospective cohort with confirmed AIS.Results: Approximately half of the prospective and total AIS cohorts presented with acute, sustained hemiparesis, and were diagnosed relatively quickly. AIS was suspected and diagnosed more slowly in the half presenting with symptoms other than sustained hemiparesis. Thirty‐one out of 51 patients with AIS (19 females, 32 males, mean age 8 years 6 months, SD 5 years 4 months) had arterial abnormalities identified by computed tomography angiography (CTA) or magnetic resonance angiography (MRA): 11 with large vessel occlusion, six with dissection, five with moyamoya disease, nine with other arteriopathies. Among these patients, those initially imaged with CTA were diagnosed more quickly than those with initial magnetic resonance imaging/angiography, which facilitated thrombectomy and thrombolytic therapy. Twenty out of 51 had AIS without arterial abnormalities on CTA or MRA: eight with lenticulostriate vasculopathy and 12 with other small‐vessel AIS. Among these patients, 80% were ineligible for thrombolysis for reasons beyond delay to diagnosis, and all showed good outcomes with supportive treatments alone.Interpretation: Clinical features at presentation influence rapidity with which childhood AIS is suspected and diagnosed. Readily available CTA can direct thrombectomy in patients with large vessel occlusion and thrombolysis in most, but not all, eligible patients.What this paper adds: Children with acute ischaemic stroke (AIS) commonly present with symptoms other than sustained hemiparesis. Stroke is more slowly recognized in these patients, which limits potential therapies. Computed tomography angiography (CTA) accurately identifies AIS with large vessel occlusion, enabling timely endovascular thrombectomy. CTA is sufficient to direct thrombolytic therapy in most eligible children. Most childhood AIS without arterial abnormalities identified by CTA had good outcomes.


  • Australian Clinical Consensus Guideline: The diagnosis and acute management of childhood stroke

    by Tanya L Medley, Christina Miteff, Ian Andrews, Tyson Ware, Michael Cheung, Paul Monagle, Simone Mandelstam, Alison Wray, Clair Pridmore, Christopher Troedson, et al.

    Stroke is among the top 10 causes of death in children and survivors carry resulting disabilities for decades, at substantial cost to themselves and their families. Children are not currently able to access reperfusion therapies, due to limited evidence supporting safety and efficacy and long diagnostic delays. The Australian Clinical Consensus Guideline for the Diagnosis and Acute Management of Childhood Stroke was developed to minimize unwarranted variations in care and document best evidence on the risk factors, etiologies, and conditions mimicking stroke that differ from adults. Clinical questions were formulated to inform systematic database searches from 2007 to 2017, limited to English and pediatric studies. SIGN methodology and the National Health and Medical Research Council system were used to screen and classify the evidence. The Grades of Recommendation, Assessment, Development, and Evaluation system (GRADE) was used to grade evidence as strong or weak. The Guideline provides more than 60 evidence-based recommendations to assist prehospital and acute care clinicians in the rapid identification of childhood stroke, choice of initial investigation, to confirm diagnosis, determine etiology, selection of the most appropriate interventions to salvage brain at risk, and prevent recurrence. Recommendations include advice regarding the management of intracranial pressure and congenital heart disease. Implementation of the Guideline will require reorganization of prehospital and emergency care systems, including the development of regional stroke networks, pediatric Code Stroke, rapid magnetic resonance imaging and accreditation of primary pediatric stroke centers with the capacity to offer reperfusion therapies. The Guideline will allow auditing to benchmark timelines of care, access to acute interventions, and outcomes. It will also facilitate the development of an Australian childhood stroke registry, with data linkage to international registries, to allow for accurate data collection on stroke incidence, treatment, and outcomes.